-
Je něco špatně v tomto záznamu ?
The evaluation of DNA-linked inhibitor antibody and AlphaScreen assays for high-throughput screening of compounds targeting the cap-binding domain in influenza a polymerase
K. Čermáková, J. Gregor, M. Kráľ, E. Karlukova, V. Navrátil, R. Reiberger, CB. Albiñana, V. Bechynský, P. Majer, J. Konvalinka, A. Machara, M. Kožíšek
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- antivirové látky * farmakologie chemie MeSH
- fluorometrie metody MeSH
- lidé MeSH
- piperidiny farmakologie MeSH
- pyridiny MeSH
- pyrimidiny MeSH
- pyrroly MeSH
- RNA čepičky metabolismus MeSH
- RNA-dependentní RNA-polymerasa antagonisté a inhibitory metabolismus MeSH
- rychlé screeningové testy * metody MeSH
- virové proteiny * antagonisté a inhibitory metabolismus MeSH
- virus chřipky A účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The PB2 subunit of the influenza virus polymerase complex is essential for viral replication, primarily through a mechanism known as cap-snatching. In this process, PB2 binds to the 5' cap structure of host pre-mRNAs, enabling the viral polymerase to hijack the host transcriptional machinery. This binding facilitates the cleavage and integration of the capped RNA fragment into viral mRNA, thereby promoting efficient viral replication. Inhibiting the PB2-cap interaction is therefore crucial, as it directly disrupts the viral replication cycle. Consequently, targeting PB2 with specific inhibitors is a promising strategy for antiviral drug development against influenza. However, there are currently no available methods for the high-throughput screening of potential inhibitors. The development of new inhibitor screening methods of potential PB2 binders is the focus of this study. In this study, we present two novel methods, DIANA and AlphaScreen, for screening influenza PB2 cap-binding inhibitors and evaluate their effectiveness compared to the established differential scanning fluorimetry (DSF) technique. Using a diverse set of substrates and compounds based on the previously described PB2 binder pimodivir, we thoroughly assessed the capabilities of these new methods. Our findings demonstrate that both DIANA and AlphaScreen are highly effective for PB2 inhibitor screening, offering distinct advantages over traditional techniques such as isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR). These advantages include improved scalability, reduced sample requirements, and the capacity for label-free detection. Notably, DIANA's ability to determine Ki values from a single-well measurement significantly enhances its practicality and efficiency in inhibitor screening. This research represents a significant step forward in the development of more efficient and scalable screening strategies, helping advance efforts in the discovery of antiviral drugs against influenza.
1st Faculty of Medicine Charles University Kateřinská 1660 121 08 Prague 2 Czech Republic
Faculty of Science Charles University Hlavova 8 128 00 Prague 2 Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010069
- 003
- CZ-PrNML
- 005
- 20250429134610.0
- 007
- ta
- 008
- 250415e20241212ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejps.2024.106990 $2 doi
- 035 __
- $a (PubMed)39674552
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Čermáková, Kateřina $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic; First Faculty of Medicine, Charles University, Kateřinská 1660, 121 08, Prague 2, Czech Republic
- 245 14
- $a The evaluation of DNA-linked inhibitor antibody and AlphaScreen assays for high-throughput screening of compounds targeting the cap-binding domain in influenza a polymerase / $c K. Čermáková, J. Gregor, M. Kráľ, E. Karlukova, V. Navrátil, R. Reiberger, CB. Albiñana, V. Bechynský, P. Majer, J. Konvalinka, A. Machara, M. Kožíšek
- 520 9_
- $a The PB2 subunit of the influenza virus polymerase complex is essential for viral replication, primarily through a mechanism known as cap-snatching. In this process, PB2 binds to the 5' cap structure of host pre-mRNAs, enabling the viral polymerase to hijack the host transcriptional machinery. This binding facilitates the cleavage and integration of the capped RNA fragment into viral mRNA, thereby promoting efficient viral replication. Inhibiting the PB2-cap interaction is therefore crucial, as it directly disrupts the viral replication cycle. Consequently, targeting PB2 with specific inhibitors is a promising strategy for antiviral drug development against influenza. However, there are currently no available methods for the high-throughput screening of potential inhibitors. The development of new inhibitor screening methods of potential PB2 binders is the focus of this study. In this study, we present two novel methods, DIANA and AlphaScreen, for screening influenza PB2 cap-binding inhibitors and evaluate their effectiveness compared to the established differential scanning fluorimetry (DSF) technique. Using a diverse set of substrates and compounds based on the previously described PB2 binder pimodivir, we thoroughly assessed the capabilities of these new methods. Our findings demonstrate that both DIANA and AlphaScreen are highly effective for PB2 inhibitor screening, offering distinct advantages over traditional techniques such as isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR). These advantages include improved scalability, reduced sample requirements, and the capacity for label-free detection. Notably, DIANA's ability to determine Ki values from a single-well measurement significantly enhances its practicality and efficiency in inhibitor screening. This research represents a significant step forward in the development of more efficient and scalable screening strategies, helping advance efforts in the discovery of antiviral drugs against influenza.
- 650 12
- $a rychlé screeningové testy $x metody $7 D057166
- 650 12
- $a antivirové látky $x farmakologie $x chemie $7 D000998
- 650 12
- $a virové proteiny $x antagonisté a inhibitory $x metabolismus $7 D014764
- 650 _2
- $a virus chřipky A $x účinky léků $7 D009980
- 650 _2
- $a RNA čepičky $x metabolismus $7 D012315
- 650 _2
- $a RNA-dependentní RNA-polymerasa $x antagonisté a inhibitory $x metabolismus $7 D012324
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a fluorometrie $x metody $7 D005470
- 650 _2
- $a piperidiny $x farmakologie $7 D010880
- 650 _2
- $a pyridiny $7 D011725
- 650 _2
- $a pyrimidiny $7 D011743
- 650 _2
- $a pyrroly $7 D011758
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gregor, Jiří $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic; First Faculty of Medicine, Charles University, Kateřinská 1660, 121 08, Prague 2, Czech Republic
- 700 1_
- $a Kráľ, Michal $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic; First Faculty of Medicine, Charles University, Kateřinská 1660, 121 08, Prague 2, Czech Republic
- 700 1_
- $a Karlukova, Elena $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic
- 700 1_
- $a Navrátil, Václav $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic
- 700 1_
- $a Reiberger, Róbert $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic; Faculty of Science, Charles University, Hlavova 8, 128 00, Prague 2, Czech Republic
- 700 1_
- $a Albiñana, Carlos Berenguer $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic
- 700 1_
- $a Bechynský, Vít $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic
- 700 1_
- $a Majer, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic
- 700 1_
- $a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic; Faculty of Science, Charles University, Hlavova 8, 128 00, Prague 2, Czech Republic
- 700 1_
- $a Machara, Aleš $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic. Electronic address: ales.machara@uochb.cas.cz
- 700 1_
- $a Kožíšek, Milan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic. Electronic address: milan.kozisek@uochb.cas.cz
- 773 0_
- $w MED00001639 $t European journal of pharmaceutical sciences $x 1879-0720 $g Roč. 205 (20241212), s. 106990
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39674552 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134606 $b ABA008
- 999 __
- $a ok $b bmc $g 2311437 $s 1247150
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 205 $c - $d 106990 $e 20241212 $i 1879-0720 $m European journal of pharmaceutical sciences $n Eur J Pharm Sci $x MED00001639
- LZP __
- $a Pubmed-20250415